Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Methycure Biotech Corp. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, SWITZER, JULIET CAROLINE, who is the only individual currently reviewing the company's applications. Having 1 pending action suggests that the company's current patent activity is highly focused on a specific project.
The prosecution involves 1 distinct art unit. SWITZER, JULIET CAROLINE is the busiest examiner with 1 pending action, which represents the total current workload for the company. This concentration in 1 distinct art unit under a single point of review means that the company's immediate patent success is tied to a specific examiner's interpretation. Practitioners should focus on the examination style of SWITZER, JULIET CAROLINE, as there are no other art units to provide a baseline for comparison within the current portfolio. The 1 pending action defines the company's current interaction with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245619 | PATHOGEN SPECIFIC NUCLEIC ACID FRAGMENT AND APPLICATION THEREOF | SWITZER, JULIET CAROLINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245619 | PATHOGEN SPECIFIC NUCLEIC ACID FRAGMENT AND APPLICATION THEREOF | SWITZER, JULIET CAROLINE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18245619 | PATHOGEN SPECIFIC NUCLEIC ACID FRAGMENT AND APPLICATION THEREOF | SWITZER, JULIET CAROLINE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMethycure Biotech Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Juliet Caroline Switzer has the most, with 1 of Methycure Biotech Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
